Skip to main content
Equibles
ANIK logo

ANIK · Anika Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track ANIK — free

Use ANIK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.36 -0.30 (-1.53%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the three-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
View the 10-Q filed Jul 29, 2026
Market Cap
$267.26M
Shares
13.38M
Volume · Oct 1 111.91K Avg daily vol (3M) 96.85K

Anika Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Anika Therapeutics, Inc. (ANIK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1.8% $40.26M −$4.17M '22 Q3 22-11-08 ▼107.8% $ −$4.91M '22 Q4 23-03-06 ▲3.4% $37.92M −$10.35M '23 Q1 23-05-09 ▲11.7% $44.30M −$2.74M '23 Q2 23-08-08 ▲3% $41.47M −$6.58M '23 Q3 23-11-02 · $ −$63.00M '23 Q4 24-03-13 ▼23.5% $29.02M −$4.51M '24 Q1 24-05-08 ▼30.6% $30.72M −$88,000 '24 Q2 24-08-08 ▼28.7% $29.56M −$29.92M '24 Q3 24-10-31 · $30.60M −$21.86M '24 Q4 25-03-12 ▼9.8% $26.17M −$4.87M '25 Q1 25-05-09 ▼8.2% $28.22M −$3.97M '25 Q2 25-07-30 ▼5.9% $27.82M −$2.33M '25 Q3 25-11-05 ▲0% $30.61M $292,000 '25 Q4 26-02-26 ▲13.2% $29.61M −$5.06M '26 Q1 26-04-29 LATEST ▲15.6% $32.61M $3.31M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Confident tone International OA pain management growth OEM channel and J&J / DePuy Synthes partnership Operational excellence and margin expansion
Revenue
$32.61M
▲ 15.6% YoY
Diluted EPS
$0.24
Gross margin
65.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Confident tone Integrity regenerative product performance Operational discipline and gross margin International OA Pain Management
Revenue
$29.61M
▲ 13.2% YoY
Diluted EPS
$-0.37
Gross margin
64.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Positive tone Commercial channel revenue growth International OA pain portfolio Integrity regenerative platform
Revenue
$30.61M*
▲ 0% YoY
Gross margin
62.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Positive tone Hyalofast Regulatory Pathway Cingal NDA Progress Integrity Adoption
Revenue
$27.82M
▼ 5.9% YoY
Diluted EPS
$-0.16
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Cautious tone Hyalofast Phase III Trial Results Cingal NDA Progress Integrity Product Momentum
Revenue
$28.22M
▼ 8.2% YoY
Diluted EPS
$-0.28
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Balanced tone Commercial channel growth Integrity implant traction Supply and production issues
Revenue
$26.17M
▼ 9.8% YoY
Diluted EPS
$-0.34
Gross margin
56.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Anika Therapeutics, Inc. (ANIK) Q4 2024 Earnings Call Transcript
Positive tone Integrity Implant System Growth Hyalofast Regulatory Progress Cingal Development
Revenue
$30.60M*
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
Positive tone Regenerative Solutions pipeline OA Pain Management focus Strategic restructuring and divestitures
Revenue
$29.56M
▼ 28.7% YoY
Diluted EPS
$-2.03
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Anika Therapeutics, Inc. (ANIK) Q2 2024 Earnings Call Transcript
Confident tone Regenerative product Integrity launch OA Pain Management franchise (Orthovisc/Monovisc/Cingal) Regulatory pipeline and clinical studies
Revenue
$30.72M
▼ 30.6% YoY
Diluted EPS
$0.00
Gross margin
66.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Positive tone OA Pain Management Cingal U.S. FDA Path Joint Preservation and Restoration
Revenue
$29.02M
▼ 23.5% YoY
Diluted EPS
$-0.31
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
Confident tone 2024 guidance and MDR / international Integrity Implant System OA Pain Management / Cingal
Revenue
$*
Gross margin
-199.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript
Revenue
$41.47M
▲ 3% YoY
Diluted EPS
$-0.45
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Anika Therapeutics, Inc. (ANIK) Q2 2023 Earnings Call Transcript
Revenue
$44.30M
▲ 11.7% YoY
Diluted EPS
$-0.19
Gross margin
65.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Anika Therapeutics, Inc. (ANIK) Q1 2023 Earnings Call Transcript
Revenue
$37.92M
▲ 3.4% YoY
Diluted EPS
$-0.71
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Anika Therapeutics, Inc. (ANIK) Q4 2022 Earnings Call Transcript
Revenue
$*
▼ 107.8% YoY
Gross margin
-135.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Anika Therapeutics, Inc. (ANIK) Q3 2022 Earnings Call Transcript
Revenue
$40.26M
▲ 1.8% YoY
Diluted EPS
$-0.29
▼ 825% YoY
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Anika Therapeutics, Inc. (ANIK) Q2 2022 Earnings Call Transcript
Revenue
$39.66M
▲ 4% YoY
Diluted EPS
$-0.20
▼ 144.4% YoY
Gross margin
62.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Anika Therapeutics, Inc. (ANIK) Q1 2022 Earnings Call Transcript
Revenue
$36.69M
▲ 7% YoY
Diluted EPS
$-0.20
▼ 200% YoY
Gross margin
59.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Anika Therapeutics, Inc. (ANIK) Q4 2021 Earnings Call Transcript
Revenue
$35.82M*
▲ 9.6% YoY
Gross margin
50.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Anika Therapeutics, Inc. (ANIK) Q3 2021 Earnings Call Transcript
Revenue
$39.54M
▲ 24.7% YoY
Diluted EPS
$0.04
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Anika Therapeutics, Inc. (ANIK) Q2 2021 Earnings Call Transcript
Revenue
$38.15M
▲ 24.3% YoY
Diluted EPS
$0.45
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Anika Therapeutics, Inc. (ANIK) Q1 2021 Earnings Call Transcript
Revenue
$34.29M
▼ 3.1% YoY
Diluted EPS
$0.20
▼ 50% YoY
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Anika Therapeutics, Inc. (ANIK) Q4 2020 Earnings Call Transcript
Revenue
$32.69M
▲ 9.8% YoY
Diluted EPS
$-1.10
▼ 492.9% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Anika Therapeutics, Inc. (ANIK) Q3 2020 Earnings Call Transcript
Revenue
$31.69M
▲ 6.7% YoY
Diluted EPS
$-0.45
▼ 168.2% YoY
Gross margin
54.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Anika Therapeutics, Inc. (ANIK) Q2 2020 Earnings Call Transcript
Revenue
$30.68M
▲ 0.9% YoY
Diluted EPS
$-0.54
▼ 180.6% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Anika Therapeutics, Inc. (ANIK) Q1 2020 Earnings Call Transcript
Revenue
$35.40M
▲ 43.2% YoY
Diluted EPS
$0.40
▲ 29% YoY
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Anika Therapeutics, Inc. (ANIK) Q4 2019 Earnings Call
Revenue
$29.77M
▲ 10.4% YoY
Diluted EPS
$0.28
▼ 48.1% YoY
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 898437 CUSIP 035255108 13F (30d) 3 filings 3 filers Visit website Investor relations